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Abstract: Metabolic syndrome comprises a cluster of comorbidities that represent a major risk 
of developing chronic diseases, such as type II diabetes, cardiovascular diseases, and stroke. 
Alarmingly, metabolic syndrome reaches epidemic proportions worldwide. Today, lifestyle 
changes and multiple drug-based therapies represent the gold standard to address metabolic 
syndrome. However, such approaches face two major limitations: complicated drug therapeutic 
regimes, which in most cases could lead to patient incompliance, and limited drug efficacy. This 
has encouraged scientists to search for novel routes to deal with metabolic syndrome and related 
diseases. Within such approaches, self-assembled peptide formulations have emerged as a 
promising alternative for treating metabolic syndrome. In particular, self-assembled peptide 
hydrogels, either as acellular or cell-load three-dimensional scaffoldings have reached significant 
relevance in the biomedical field to prevent and restore euglycemia, as well as for controlling 
cardiovascular diseases and obesity. This has been possible thanks to the physicochemical 
tunability of peptides, which are developed from a chemical toolbox of versatile amino acids 
enabling flexibility of designing a wide range of self-assembled/co-assembled nanostructures 
forming biocompatible viscoelastic hydrogels. Peptide hydrogels can be combined with several 
biological entities, such as extracellular matrix proteins, drugs or cells, forming functional 
biologics with therapeutic ability for treatment of metabolic syndrome-comorbidities. 
Additionally, self-assembly peptides combine safety, tolerability, and effectivity attributes; by 
this presenting a promising platform for the development of novel pharmaceuticals capable of 
addressing unmet therapeutic needs for diabetes, cardiovascular disorders and obesity. In this 
review, recent advances in developing self-assembly peptide nanostructures tailored for improv-
ing treatment of metabolic syndrome and related diseases will be discussed from basic research 
to preclinical research studies. Challenges facing the development of approved medicinal 
products based on self-assembling peptide nanomaterials will be discussed in light of regulatory 
requirement for clinical authorization. 
Keywords: peptide, hydrogel, nanomaterials, metabolic syndrome, diabetes, obesity, 
cardiovascular disease
Introduction
Metabolic syndrome (MS) comprises a cluster of metabolic abnormalities, such as 
accumulation of lipids, insulin resistance, and chronic inflammation, which ulti-
mately lead to three main long-term medical conditions, type 2 diabetes, cardio-
vascular diseases (CVDs), and ischemic stroke.1
According to the World Health Organization, alarmingly there is about 422 million 
diabetics worldwide, which have been mainly diagnosed in developing countries.2 
Moreover, CVDs represent the first cause of death globally, where 85% of CVD deaths 
are caused by heart attacks and strokes.3 With regard to obesity, in countries such as 
Correspondence: Luis Alberto Castillo- 
Díaz  
Department of Medicine and Health 
Sciences, University of Sonora, 
Hermosillo, Sonora 83000, Mexico  
Tel +52 662 2592121 Ext. 4593  
Email luis.castillo@unison.mx
International Journal of Nanomedicine                                                 Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com International Journal of Nanomedicine 2020:15 10349–10370                                          10349
http://doi.org/10.2147/IJN.S278189 
DovePress © 2020 Castillo-Díaz et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ 
terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing 
the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. 




































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Australia, Chile, Canada, South Africa, and the United 
Kingdom, more than one in four adults are obese, while the 
United States of America and Mexico, are the countries with 
more cases of diagnosed obesity in the Americas.4
The current management to address MS-related meta-
bolic abnormalities includes adopting a healthy lifestyle 
and following a long-term medication regimen.1 However, 
such a strategy is difficult to accomplish for patients, since 
various drugs are prescribed for only one pathology and 
this is expensive.5 In this context, the development of 
drugs containing more than one bioactive agent, which is 
known as the “polypill-based approach”, reduces costs, 
when generic bioactive agents are used. Nonetheless, 
research is still ongoing in order to overcome the risks of 
side effects related to such a polypill therapy.5,6
In recent years, medicine has benefitted from the technolo-
gical advances of tissue engineering and regenerative medi-
cine. Within such a technology, advanced peptide-based 
nanomaterials formed from the self-assembly of amino acids 
have regained considerable attention for the treatment of 
chronic diseases. This can be possible thanks to the inherent 
physicochemical characteristics of amino acids, which act as 
building blocks to form more complex nanofibrillar formula-
tions exhibiting high versatility and reproducibility.7,8 The 
fine-tuning of supramolecular interactions held among pep-
tides triggers either their assembly or disassembly through 
direct interactions, peptide conjugations or synthesis strategies. 
This approach relies on non-covalent interactions, such as 
hydrogen bonding, electrostatic, hydrophilic and hydrophobic, 
van der Walls, and pi-stacking. Thus, naturally occurring, 
secondary structures, such as β-sheet, β-turns, random coils, 
and α-helix, ultimately lead to the formation of nanostructured 
fibers, fibrils, micelles, ribbons, tapes, etcetera.9,10 Peptide 
assembly and disassembly are held under specific conditions 
and well-controlled conditions, which include enzymatic 
conjugation,11 pH,12 or ionic strength responsiveness,13 all of 
them offering significantly advantages for biomedical 
applications.14
Therefore, from a wide library of amino acids and their 
equally possible combinations, various peptides can be 
formulated to design peptide-based nanostructures, such 
as dimensional (3D) hydrogels, solutions, and other 
matrices as pharmaceuticals with significant potential to 
tackle metabolic syndrome and its related comorbidities.7
Since their serendipitously discovery in 1990, self-assem-
bling peptide hydrogels (SAPHs) are ubiquitous in medicinal 
chemistry and for more than twenty years, they have extended 
their biomedical applications. Studies have focused to design 
SAPHs to act as three-dimensional (3D) matrices for the 
encapsulation of mature15–17 and stem cells,18–20 as well as to 
deliver biological entities, such as growth factors and drugs in a 
sustained and controlled manner. Other applications for 
SAPHs include, bioprinting for tissue engineering, stabiliza-
tion of membrane proteins (G-protein), and more recently, 
some SAPHs have reached clinical trials to help wound 
healing.21
With respect to metabolic syndrome, the design of self- 
assembling peptides is being exploited for the develop-
ment of advanced 3D gels that, when combined with key 
biomolecules7,22,23 or cells,24 represent a promising alter-
native to regenerate damaged tissues of patients under-
going hyperglycemia, CVDs, and other related, since the 
predictable metabolism along with reproducible protocols 
to form such scaffoldings is being increasingly refined. 
Furthermore, peptide-based formulations, such as matrices 
or solutions are being designed to develop novel pharma-
ceutics with increased efficacy, safety, and tolerability for 
treating hyperglycemia25 and obesity.26 In this review, the 
potential and current limitations related to peptide-based 
formulations to address metabolic syndrome and related 
chronic diseases are concisely provided and discussed.
Metabolic Syndrome (MS), An 
Overview
MS is a medical condition characterized by abdominal obe-
sity, insulin resistance, hypertension, and hyperlipidemia, 
which alarmingly has become the main non-communicable 
disease health hazard worldwide.1,27 Type 2 diabetes, coron-
ary pathologies, and stroke represent the major diseases 
derived from MS. Overall, the etiology of this hazardous 
syndrome consist on long term industrialized food consump-
tion, which is characterized by a high caloric and low fiber 
element, as well as prolonged physical sedentarism.27
According to the National Cholesterol Education 
Program Adult Treatment Panel III, three or more of the 
criteria listed in Table 1 are required for MS diagnose.28,29 
However, it also has to be noted that the criteria to diagnose 
MS may vary depending on the age, gender, and ethnic origin 
of the subjects. The pathophysiology of MS is complex and is 
highly dependent on the gradual distortion of metabolic 
homeostasis, which ultimately leads to the impairment of 
the physiological functions of several organs and tissues. 
The reader is referred to The metabolic syndrome (chapter 
3), for a deeper understanding in this matter.30
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In 2016, 17.9 million people died from CVDs, and 
85% from such deaths were due to heart attack, and stroke. 
Likewise, more than 75% of CVD deaths occur in low- 
income and mild-income countries.3 In the same year, 
diabetes mellitus (DM) caused the death of about 1.6 
million subjects, which placed this pathology as the 
seventh leading cause of death globally.2 In the European 
region about 60 million people have been diagnosed with 
diabetes and such an epidemiologic profile continues to 
increase among all ages each year.32 In the Americas, the 
epidemiologic profile is even less encouraging, since in the 
United States of America, about 71,000 people died from 
diabetes in the same year,33 while in Mexico, 87,000 
deaths were recorded.34
Medical associations worldwide recommend changes of 
lifestyle, which include a reduction of caloric intake, increas-
ing physical activity, and encouraging weight loss as a first 
alternative for MS treatment. In addition, before any phar-
macological prescription, MS treatment recommendations 
include monitoring full lipid and thyroid hormones, as well 
as exploring liver function and urine albumin to 
discard further metabolic abnormalities.1,29 (Table 2). 
Unfortunately, such management is not completely effective 
for all patients.29
Table 1 Representative of Diagnosis Criteria for Metabolic Syndrome
Comorbidity Diagnosis Ref.
Central obesity Waist circumference > 102 cm (males) or > 88 cm (females). 31
Lipid profile Triglycerides ≥ 150 mg/dl.31 
HDL-cholesterol < 40 mg/dl (males) or < 50 mg/dl (females).
31
Blood pressure ≥ 130/85 mm Hg. 31
Hyperglycemia Fasting glucose ≥ 110 mg/dl (modified to > 100 g/dl (diabetes). 31
Table 2 Representative of the Gold Standard for the Treatment of Metabolic Syndrome
Risk Factor Strategies Ref.
Abdominal obesity First year: reduction of body weight 7% - 10%. 
Weight loss with a final BMI goal < 25kg/m2.
35,36
Physical Inactivity Carry out continuous physical activity (ca. 30 min) or at moderate intensity (5 times a week). 35,37,38
Diet Reduction intake of saturated fat, trans fat, and cholesterol. 
Follow Mediterranean diet. 
Follow DASH. 
Lowering carbohydrates index. 
High fiber diet > 30g/day.
35,37,39,40
Dyslipidemia. 
High LDL cholesterol. 
High non-HDL cholesterol. 
Reduced HDL cholesterol.
Lowering LDL cholesterol < 130 mg/dl or  
< 100 mg/dl, and < 70 mg/dl for high and very high risk, repectively. 
Triglycerides ≥ 200 mg/dl, non-HDL cholesterol is a second goal. 
Increase of HDL cholesterol as a third goal (at non-specified values).  
Statin-based treatment.
36,38,39,41
High blood pressure Antihypertensive drugs must be introduced even at lower blood pressures (< 140/90). 36,38,42,43
High glucose For IFG, encourage weight reduction and physical activity. 
Metformin and other oral hypoglycemic agents. 
Achieve glycosylated hemoglobin to 7% or less.
36,38,43
Prothrombotic state Low-dose acetylsalicylic acid for high-risk patients. 36
Proinflammatory state Lifestyle therapies. 36
Habits Avoid smoking and alcohol. 35,38
Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein; DM, diabetes mellitus; IFG, impaired fasting glycaemia; DASH diet, dietary approaches to stop 
hypertension; BMI, body mass index.
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Therefore, the prescription of pharmacological therapy 
under medical supervision is needed. The standard phar-
macotherapy for MS treatment and related comorbidities 
includes hypoglycemic, antihypertensive, and anticholes-
teremic drugs (Table 3).1
However, such a drug management faces various lim-
itations. Firstly, drug regimens are often difficult to be 
accomplished for patients, since separate drugs are pre-
scribed for only one MS-related medical condition. This 
also complicates medical monitoring by practitioners. 
Secondly, the prescription of various drugs increases the 
risk of pharmacological secondary effects. Lastly but not 
least, such pharmacological regimen is highly expensive.5 
Overall, this scenario causes scientists to seek new strate-
gies to overcome the current limitations of MS manage-
ment, where self-assembled peptides have reemerged as a 
promising route for patients undergoing MS.
Design Approaches of Self-Assembling 
Peptide Nanostructures and Hydrogels 
for MS Applications
A bottom-up design approach has been adopted by biomater-
ials engineers for the development of self-assembling pep-
tide-based nanostructures. This approach involves using a 
chemical toolbox of amino acid building blocks for the 
rational design of a peptide primary sequence, which is pur-
posely developed to adopt a bioinspired secondary structure 
capable of self-assembly into higher nanostructures 
(Figure 1A). Self-assembly occurs via non-covalent interac-
tions between peptide chains involving hydrogen bonding 
between peptide backbone amides, as well as between side-
chains, Van der Waals, hydrophobic interactions, pi-stacking 
between aromatic residues, and electrostatic interactions 
between charged residues.9,10 For instance, peptides designed 
to acquire α-helical structures via inter-chain hydrogen bond-
ing and self-organize/co-organize into coiled-coil structures 
via hydrophobic and electrostatic attraction, forming nano-
tubes as well as rigid extended nanofibers (Figure 1B).46–50 In 
contrast, β-sheet forming peptides are typically ionic-comple-
mentary sequences inspired from the unusual sequence pat-
tern of the baker’s yeast Zuotin protein domain,51–53 which 
were designed to self-assemble via backbone amide inter- 
chain interactions forming extended, but more flexible, β- 
sheet nanofibers that entangle to form hydrogels at a relevant 
critical gelation concentration (Figure 1C).54–58 Similarly, β- 
hairpin forming peptides are longer sequences designed with 
“kink-forming” residues in the middle, usually prolines, 
which upon bending can self-assemble via intra-chain hydro-
gen bonding between peptide backbone amides and lateral 
association of hairpins into β-sheet like nanofibrous structures 
forming hydrogels (Figure 1D).59–61 Self-assembling short 
aromatic peptides were designed inspired by amyloid pep-
tides with diphenyl alanine (FF) in the sequence core, which 
are believed to drive self-assembly through aromatic pi- 
stacking.62 Short aromatic peptide sequences are, thus, either 
formed of aromatic residues or capped with aromatic protect-
ing groups, such as fluorenylmethoxycarbonyl (Fmoc), car-
boxybenzyl (CBZ), or naphthyl (Naph) groups, to facilitate 
self-assembly through pi-stacking into nanofibers capable of 
hydrogelation (Figure 1E).63–65 Single amino acids capped 
with aromatic protecting groups also showed to self-assemble 
into nanofibrous structures forming hydrogels.66–68 
Amphiphilic peptides, contrarily, are surfactant-like structures 
with a hydrophilic peptide sequences capped with long hydro-
phobic hydrocarbon chains that are capable of self-assembly 
into micellar cylinders forming nanofibrous hydrogels in aqu-
eous media (Figure 1F).69–71 Amphiphilic block copolypep-
tide designs have also shown hydrogelation capacity.72–74 
Self-assembly could be triggered for these de novo peptides 
by manipulating the external environment conditions, which 
could be thermal,58,75,76 photo,77–79 or enzymatic triggers,-
11,80–82 as well as dramatic changes in pH,54,83 and ionic 
strength.60,84,85
Self-assembling peptide nanostructures and hydrogels 
have a great potential for therapeutic, pharmaceutical and 
biomedical applications, thanks to the versatility of the 
designs as discussed above, the ease of synthesis and chemi-
cal functionalization, physicochemical tunability, biocom-
patibility and biodegradability. In addition, these are in 
most cases viscoelastic shear thinning and thixotropic soft 
materials, implying injectability and sprayability. By virtue 
of these attributes, peptide hydrogels have been used as 
therapeutic materials, and cellular scaffolds as potential treat-
ment strategies for medical conditions associated with meta-
bolic disorders. As therapeutic materials, the self-assembling 
peptide sequence itself possesses pharmacological activity. 
Peptide hydrogels have also been widely used as delivery 
vehicles for a wide variety of drug treatments for metabolic 
conditions, which can act as drug depot formulations22,86–91 
for stabilizing and delivering drug molecules vulnerable to 
metabolic degradation, such as the anti-diabetic drugs DPP- 
IV inhibitor sitagliptin,87 and insulin.86,88 The stabilization 
capacity of such hydrogels also made them optimal vehicles 
for the delivery of growth factor proteins for tissue regenera-
tion and repair in CVDs,91–93 and for facilitating 
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Table 3 Representative of the Pharmacological Therapy for Metabolic Syndrome
Comorbidity Drugs Mechanism of Action Ref.
Obesity Lipase inhibitor. 
Orlistat.
Inhibit gastric and pancreatic lipases, which leads to breakdown dietary fat. 
The administration of orlistat decreases fat absorption ca. 30%.
44
Dyslipidemia HMG-CoA reductase inhibitors (Statins). 
Atorvastatin, Lovastatin, Simvastatin, 
Rosuvastatin, Pravastatin, Ezetimibe.
Inhibit HMG CoA reductase to limit intracellular cholesterol synthesis. 
Statins also increase the number of cell surface LDL receptors that bind and 




Activate PPARs to decrease triglyceride concentrations through a dual 
response, increasing the expression of lipoprotein lipase and decreasing the 




Inhibit lipolysis in adipose tissue, through the reduction of the production of 
free fatty acids. The reduction of liver triglyceride levels decreases hepatic 
VLDL production, which in turn reduces LDL-C plasma concentrations.
44
PCSK9 inhibitors. Since PCSK9 is involved in the degradation of LDL receptors in the liver, 
blocking its activity with monoclonal antibodies reduces the degradation of 





Reduce hepatic gluconeogenesis and slow the intestinal absorption of 




Agonist effect on PPARγ, which leads to lowering insulin resistance. This 
results in an increased insulin sensitivity in various tissues, such as the 
adipose tissue, liver, and skeletal muscle.
44
Hypertension Angiotensin-converting enzyme (ACE 
inhibitor). 
Captopril, Enalapril, Ramipril, Quinapril, 
Lisinopril, Fosinopril.
Lower blood pressure through the reduction of peripheral vascular 
resistance, which increases cardiac output, heart rate, and contractility. 
Likewise, block the enzyme ACE, which cleaves angiotensin I to form the 




Angiotensin II receptor blockers (ARBS). 
Losartan, Valsartan, Irbesartan, 
Candesartan, Telmisartan, Eprosartan, 
Olmesartan
ARBS exert an antagonist action on AT1 receptors leading to the 
impariment of several angiotensin II effects, such as vasoconstriction. Thus, 
ARBS produce arteriolar and venous dilation, as well as inhibit aldosterone 
secretion, which ultimately decreases blood pressure, as well as salt and 
water retention.
44
Calcium channel blockers. 
Amlodipine, Diltiazem, Verapamil, 
Dihydropyridine.
Impair inward internalization of calcium into cells once bind to L-type calcium 
channels in the heart and in smooth muscle of the coronary and peripheral 
arteriolar vasculature. This causes vascular smooth muscle relaxation, and 




Decrease the reabsorption of Na+ on the cortical region of the ascending 
loop of Henle and the distal convoluted tubule. It is believed that Thiazides 
inhibit the Na+/Cl− cotransporter on the luminal membrane of the renal 
tubules (having a lesser effect in the proximal tubules). Thiazides increase 




Inhibit thromboxane A2 synthesis through the acetylation of a serine 
residue on the active site of COX-1, which irreversibly inactivates such an 
enzyme. This favors the anti-aggregation effects of prostacyclin, preventing 
platelet aggregation.
44
Abbreviations: AT1, angiotensin type 1; COX-1, cyclooxygenase-1; HMG-Co-A, 3-hydroxy-3-methyl-glutharyl-coenzyme A reductase; LDL, low-density lipoprotein; LDL- 
C, low-density lipoprotein cholesterol; PPARs, peroxisome proliferator–activated receptors; PPARγ, peroxisome proliferator–activated receptor gamma.
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transplantation of pancreatic islets as a new treatment strat-
egy for diabetes.17,94–98
Despite the significant research efforts in the develop-
ment of peptide-based biomaterials for a variety of biome-
dical applications, only a few studies have focused on the 
development of such materials for the treatment metabolic 
syndrome-associated factors (MSAFs), such as hypergly-
cemia, hypertension, hypercholesteremia, as well as for 
tackling long-term pathologies derived from MS. In the 
next sections, such research, will be presented.86,99
Acellular Self-Assembled Peptide 
Hydrogels for the Treatment of 
Hyperglycemia
The self-assembly of peptides represents a straightforward 
and cost-effective approach to form biocompatible hydro-
gels through a minimalist Fmoc chemistry focused on 
overcoming hyperglycemia. Peptide systems have been 
synthesized to form self-supported SAPHs with remark-
able diffusion, mechanics, and nanofibrillar architecture 
highly suitable for biomedical applications. Thus, one of 
the most remarkable approaches to address either type I 
(TIDM) or type II diabetes mellitus (TIIDM) is exploiting 
the assembly and disassociation of peptides to form hydro-
gels capable of encapsulating and delivering various types 
of proteins, drugs, and cells to drive biological responsive-
ness. Moreover, recent studies explore the rationale stabi-
lization of peptide-based formulations to develop novel 
antidiabetic pharmaceutics with desirable pharmacody-
namic and pharmacokinetic profiles.100,101
The fine-tuning of peptide pH-responsiveness within pep-
tide formulations is an alternative to meet hyperglycemia. An 
example of this is the glucose responsive β-sheet-based pep-
tide hydrogel RATEA-16 also known as F0 hydrogel, which 
has shown a good potential to release bovine insulin 
Figure 1 Depiction of bottom-up design approach for de novo peptides capable of self/co-assembly into different classes of bioinspired nanofibrous structures. (A) Amino 
acids acting as building blocks form hierarchical structures, such as (B) α-helix (C) β-sheet, (D) β-hairpin, (E) short aromatic, and (F) amphiphile peptides. Dashed lines 
denote hydrogen bonds. 
Note: Micellar Cylinder and Amphiphile Structure taken from Hartgerink JD, Beniash E, Stupp SI. Self-assembly and mineralization of peptide-amphiphile 
nanofibers. Science. 2001;294,(5547):1684–1688. doi:10.1126/science.1063187. Reprinted and modified with permission from AAAS.72
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(Figure 2). In order to facilitate the encapsulation of insulin 
and the subsequent peptide hydrogel disassembly, alanine 
residues were substituted by valine and isoleucine throughout 
the peptide backbone. Both, valine and isoleucine are known 
to display more hydrophobic forces. In addition, arginine was 
substituted by ornithine to favor the disassembly of the 
RATEA-16 hydrogel. The disassembling of the peptide hydro-
gel is driven by electrostatic repulsions held between ornithine 
residues at low pH conditions, as a result of the activity of both 
catalase and glucose oxidase (GO), which convert glucose into 
gluconic acid (Figure 2A1). Such a continuous release of 
insulin is held at a glucose concentration-dependent manner 
to restore euglycemia in vitro and in vivo over 12 h with no 
signs of toxicity (Figure 2A2 and A3).
The human oxyntomodulin (Oxm) peptide, which is a 
37-amino acid proglucagon derived peptide with high 
homology to both glucagon and glucagon-like peptide 1 
(GLP-1), is capable of self-assembling into a nanofibrillar 
hydrogel-like conformation. The self-assembly of Oxm 
gels takes place under ionic strength, well-controlled phy-
siological pH conditions, and following one-step dilution 
with Oxm peptide solution (non-fibrillar Oxm). 
Interestingly, Oxm hydrogels succeeded to boost an ago-
nist effect on CHO cells genetically engineered to express 
both human glucagon and GLP-1 receptors. After a single 
subcutaneous injection with Oxm gels, cAMP significantly 
increased and circulating glucose levels dropped in wild- 
type mice over 5 h, as recorded by tolerance glucose 
assays. According to the authors, such an encouraging 
outcome might be facilitated by the progressive disasso-
ciation of Oxm gels, which ultimately led to the slow 
release of monomeric entities exhibiting a larger bioactiv-
ity in comparison to the treatment with the non-fibrillar 
Oxm peptide formulation at the same dosage. Thus, Oxm 
gels represent a promising route to develop novel drugs, 
capable of assembling and dissociate under mild condi-
tions to restore euglycemia with a prolonged lifespan in 
comparison to hypoglycemic pharmaceuticals. However, 
exploring the role of Oxm for anti-obesity therapeutics 
remains on the lookout for further research.25
The incorporation of whole proteins within SAPHs is 
another widely used approach for biomedical applications. 
Incretins, such as glucagon like peptide-1 (GLP-1) play a 
critical role promoting the release of insulin following 
meal intake. Nevertheless, such proteins are rapidly inac-
tivated (ca. 2–3 min) by the gastrointestinal enzyme dipep-
tidyl peptidase-4 (DPP-IV), whose high expression can 
lead to the development of TIIDM. In order to target 
such metabolic imbalance, the capability of RADA16-II 
gels to encapsulate hempseed protein hydrolysates (food 
protein hydrolysates) and sitagliptin (an oral hypoglycemic 
DPP-IV inhibitor) both known to offer hypoglycemic 
activity was assessed. When RADA16-II encapsulating 
both hypoglycemic biologics was transferred in situ and 
ex vivo (Caco-2 cells and human serum, respectively), a 
synergic drug effect was achieved, since a significant 
reduction on the activity of DPP-IV was recorded at 
reduced dosage of sitagliptin over 10 minutes, showing 
the capability of RADA16-II to protect the hypoglicemiant 
molecules from degradation with no signs of toxicity. 
Considering that GLP-1 has a very short lifespan under 
physiological conditions, the results derived from this 
research make RADA16-II an attractive scaffold to extend 
and optimize the effectivity of hypoglycemic entities.87
RADA-16-II peptide gel was the first ionic-comple-
mentary SAPH discovered in the field, which is currently 
commercialized as PuraMatrixTM. RADA16-II is formed 
from the self-assembling of β-sheet forming peptide Ac- 
(RADA)4-CONH2, which upon subcutaneous injection 
undergoes sol-to-gel transition forming a stable nanofi-
brous hydrogel depot formulation. Nowadays, one of the 
most recent biomedical applications of RADA16-II 
includes supporting the encapsulation of antidiabetic bio-
logics to restore the function of pancreatic tissue and 
cells.21,87 Yoon et al used RADA16-II as a biological 
vehicle to encapsulate the synthetic immunostimulatory 
oligonucleotide CpGODN1826 (CpG), granulocyte macro-
phage colony-stimulating factor (GM-CSF), and poly (lac-
tide-co-glycolide) (PLGA) microparticles containing 
human insulin. The peptide hydrogel formulation boosted 
the production of IL-10, which according to the authors, 
led to an immune tolerance-like effect that ultimately 
restored euglycemia and prevented the development of 
TIDM in vivo. It is believed that both CpG and GM-CSF 
in RADA16-II gels played a key role as adjuvants to 
trigger the production of IL-10. This research clearly high-
lights the versatility of SAPHs as alternative biologics for 
the development of novel antidiabetic vaccines.99
Cell-Load Self-Assembled Peptide 
Hydrogels for the Treating 
Hyperglycemia
Although hyperglycemia derived from TIDM is not 
directly related to MS, it is worth to address the state of 
the art of SAPHs applications in this matter. More than 20 
Dovepress                                                                                                                                                   Castillo-Díaz et al
International Journal of Nanomedicine 2020:15                                                                          submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Figure 2 Representative of both (A) acellular and (B) cellular peptide-based hydrogel approaches to tackle hyperglycemia. (A1) Glucose-responsive peptide hydrogel encapsulating 
insulin and enzymes is A2) transferred into diabetic animals A3’) to reduce the levels of glucose and A3’’) maintaining normoglycemia up to 8 days. I = insulin, E = enzymes. B1) Nanomatrix 
gel encapsulating human islets and inflammatory cells, B2’) supports de viability of human islets (green fluorescent color) under an inflammatory environment in comparison to B2’’) bare 
islets, whose viability is impaired (red fluorescent color) over 7 days of culture. B3) Insulin secretion by human islets cultured inside Nanomatrix is higher in comparison to bare islets 
without Nanomatrix under an inflammatory environment at days 3 and 7. PD = human islets cocultured with inflammatory cells in Nanomatrix, BD = bare islets cocultured with 
inflammatory cells, BI = bare islets, PI = islets encapsulated in Nanomatrix. Scale bar = 200 μm. Figure 2A was adapted with permission from Inyectable self-assembled peptide hydrogels 
for glucose mediated insulin delivery. M. Fu, Ch. Zhang, Y, Dai, X, Li, M, Pan, W, Huang, H, Qian and L. Ge. Biomaterials Science 6 (6), 1480–1491, 2018. https://pubmed.ncbi.nlm.nih.gov/ 
29623975/. The Royal Society of Chemistry.88 Figure 2B Copyright ©2017. American Chemical Society. Adapted from Hwang PTJ, Shah DK, Garcia JA, et al. Encapsulation of human islets 
using a biomimetic self-assembled nanomatrix gel for protection against cellular inflammatory responses. ACS Biomater Sci Eng. 2017;3(9):2110–2119. doi:10.1021/ 
acsbiomaterials.7b00261.108
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years have passed, since intraportal islet transplantation 
(Edmonton’s protocol) was established as an encouraging 
approach to meet TIDM. However, such a therapy very 
often fails due to the poor retention and low viability of 
islets once grafted into the affected tissue. Three major 
facts cause the failing of islet transplantation, which 
include an exacerbated inflammatory process, oxidative 
stress, and autoimmune reactions.102 Today, both synthetic 
and naturally derived hydrogels are developed to provide 
protection to pancreatic cells from harsh environments 
after transfer in vivo and in situ. Overall, these biomater-
ials have achieved remarkable outcomes to potentially 
improve insulin independence in diabetics.103–106
Within peptide formulations, one major successfully 
approach is functionalizing peptide gels with extracellular 
matrix moieties, such as RGD (fibronectin), YIGSR (lami-
nin), and LRKKLGKA (vascular endothelial growth factor 
[VEGF]), to provide them with key biological signals to 
direct cellular functions in a well-controlled manner in 
comparison to other naturally-derived formulations.89
Within the family of self-assembling peptides, amphi-
philic peptides formed by a hydrophobic alkyl tail, a hydro-
gen-bonding peptide, and a charged hydrophilic head have 
achieved encouraging outcomes. Such is the case of the 
alkylated PA Nanomatrix (GTAGLIGQRGDS), which has 
shown to be suitable to support the culture and function of 
human islets over 7 days in vitro, as islets could be pro-
tected from inflammatory environments derived from dif-
ferentiated monocytes. Moreover, human islets maintained 
insulin production within gel after high glucose stimulation 
in comparison to non-encapsulated cells (Figure 2B). This 
encouraging outcome could be facilitated by RGD, which 
was exposed throughout the nanofibrillar architecture of 
gels.107 This result is in good agreement with previous 
research showing the key role that RGD-functionalized 
Nanomatrix had in improving the biological functions of 
murine insulin-producing cells in vitro.108
Another approach evaluated the positive effect that 
nitric oxide (NO) had on the viability and functions of 
murine β-cells after being released from Nanomatrix. 
Therefore, this hydrogel was designed from two functiona-
lized peptides, the first one linking YIGSR and the second 
one offering a polylysine NO donor linked to a metallopro-
teinase-2 (MPP-2) biodegradable site to allow NO deliver-
ing in a well-controlled manner. Nanomatrix increased the 
viability of murine β-cells (MIN-6 cells), as well as the 
production of insulin under glucose stimulation, which 
was dependent on the NO release from gels, particularly 
at low rates (32.5 mmol and 35 mmol).109 However, opti-
mizing this approach in order to discard any risk of negative 
effects derived from NO before considering using 
Nanomatrix-NO for clinical trials would be needed.
In an attempt to mimic the angiogenic activity of 
heparin, the heparin-mimetic peptide hydrogel HM-PA 
was designed to favor angiogenesis and to bind growth 
factors involved in wound repairing. HM-PA is another β- 
sheet structured hydrogel that offers a heparin-like bioac-
tivity and succeed to promote the viability and function of 
murine islets when cultured along with FGF and VEGF for 
7 days. Moreover, the transfer of murine islets encapsu-
lated within HM-PA hydrogels restored euglycemia during 
28 days in diabetic rats, as a higher production of insulin, 
and angiogenesis was recorded in comparison to the trans-
fer of islets without gels.17
Further research explored the biofunctionalization of 
amphiphilic peptides with the biomimetic GLP-1 receptor 
Ser [2] exendin (HSEDTFTSD) to form α-helix based 
nanofibrillar self-supported hydrogels capable of allowing 
the culture of murine insulin-producing cells (RIN-m5F 
cells). GLP-1 hydrogels successfully supported the viabi-
lity of murine β-cells in 3D cultures and promoted the 
production of insulin in a greater extent in comparison to 
exendin-4 under inflammatory conditions.110 These studies 
highlight the remarkable advantages that SAPHs offer to 
restore euglycemia. However, the development of refined 
protocols to allow a precise control of functionalities to 
direct cellular functions is still undergoing.
Furthermore, the incorporation of whole proteins to 
improve the functions of pancreatic cells has also shown 
good results. For instance, the KLD12 peptide hydrogel, 
when mixed with the negatively charged heparin known to 
have affinity to the hepatocyte growth factor (HGF), VEGF, 
and the fibroblastic growth factor (FGF), favored the reten-
tion of heparin and HGF through electrostatic interactions, 
which led to help the viability of murine β-cells and the 
production of insulin in 3D cell cultures under inflammatory 
conditions. In addition, the infiltration of T lymphocytes and 
the expression of IL-1 were significantly reduced after 
KLD2R treatment in vivo, which according to the authors 
could be majorly facilitated by HGF.95 Previously, the 
KLD2R hydrogel functionalized with biological cues 
belonging to fibronectin, and collagen improved the produc-
tion of insulin from murine β-cells in vitro.96
Other examples for the cellular treatment of DM 
involved the use of self-assembling heparin-binding pep-
tide amphiphiles nanofibers for the delivery of VEGF and 
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the fibroblast growth factor-2 (FGF-2), which successfully 
induced vascularisation and improved engraftment of syn-
geneic islets, when transplanted in a diabetic mouse with 
maintaining normoglycemia in a high proportion of the 
tested animals.98 Moreover, PuraMatrixTM was used as 
vehicle for the sustained release of murine insulin after 
subcutaneous injection in rats. Sustained release of murine 
insulin was achieved from this simple formulation, which 
maintained low blood glucose level for 24 hours in rats.97
Today, most peptide formulations designed in the field 
offer good biocompatibility, however, the potential immu-
nogenicity derived from peptides itself or peptide-derived 
aggregates is still controversial.111–113 This fact makes it 
necessary to carry out further research to discard any 
immunological effects related to peptide gels, when trans-
ferred into pancreatic tissues in vivo, before considering 
their therapeutic applications.
Overall, although the aforementioned studies discussed 
here highlight the significant role that peptide hydrogels have 
to protect β-cells from harsh environments and allow their 
biological functions in a well-controlled manner (Figure 2B), 
some relevant facts still need to be considered to place pep-
tide gels as a cutting-edge technology for treating hypergly-
cemia. One major factor to be considered is the rational use 
of primary human cells under harsh enzymatic microenvir-
onments that better reflect the human physiological condi-
tions. This turns out relevant, since, despite the remarkable 
biochemical features attributed to SAPHs, their mechanics 
and stability are two major concerns, which is mainly true 
when they are subject to in vivo environments, since SAPHs 
are inherently dynamic, biodegradable, and fluctuant scaf-
foldings susceptible to temperature and enzymatic 
activity. This ultimately leads to their easy erosion and 
degradation.83,100,101,114 Another key factor is time, thus, 
using long kinetics during research is needed to push the 
mechanics and stability of peptide gels to their boundaries, 
which ultimately would facilitate the acquisition of reliable 
outcomes to determine the suitability of SAPHs as effective 
3D vehicles to restore euglycemia and to improve islets 
grafting with no doubts of premature degradation.104, 105
Self-Assembled Peptide 
Formulations for Obesity Treatment
Some studies have focused on the design and develop-
ment of novel self-assembled peptide formulations (non- 
hydrogels) to address obesity. The lipopeptide PYY is a 
gastrointestinal hormone involved in the reduction of 
appetite following food intake. In an attempt to obtain 
PYY analogous offering effective, more stabilized and 
safe anti-obesity properties, it has been explored the 
design of three PYY derivates, which acquire β-hairpin 
and α-helix nanostructured conformations in solution. 
Following lipidation via palmitoyl chains linked to three 
different positions, particularly in residues serine (posi-
tion 11), and arginine (positions 17 and 23) throughout 
the peptide backbone, various nanostructured matrices 
such as α-helix based micelles, β-hairpin nanofibrils, 
and nanotapes could be formed. Such peptide conforma-
tions assembled under physiological pH and in a tem-
perature-dependent manner. Hence, the synthetic PYY 
formulations could facilitate the development of novel 
peptide solutions or peptide hydrogels with high potential 
to be used as pharmaceutics to address obesity in a more 
stable and extended manner in comparison to medica-
tions, such as Liraglutide.26 Nevertheless, further 
research would shed light for a deeper understanding of 
the assembly of PYY peptides to develop effective and 
safer anti-obesity drugs.
In 2014, Pellegrinelly et al reported that human 
adipocytes isolated from obese patients decreased their 
lipolysis activity after following mechanical compres-
sion when encapsulated in RADA16-II. Furthermore, 
adipocytes increased their expression rates of proinflam-
matory cytokines, fibrotic molecules and collagens. 
Interestingly, such cellular responses observed within 
gels after mechanical stress, are strongly linked to 
impaired lipid mobilization and the formation of fibrotic 
adipocyte tissue in obese subjects, which ultimately 
leads to insulin resistance. Therefore, this study high-
lights the key role that β-sheet SAPHs have as 3D 
extracellular mimicking platforms to facilitate basic 
research to understand and elucidate relevant biological 
responses for biomedical applications.115
Self-Assembled Peptides for 
Treatment Cardiovascular Affections
As mentioned above, acute myocardial infarction (AMI) 
represents a serious public health problem around the 
world. Unfortunately, the current therapeutics to address 
AMI, which include pharmacotherapy, ventricular assist 
devices, dialysis, as well as surgical procedures are not 
capable of restoring cardiac functions yet.116,117 In this 
regard, acellular and cell-load SAPHs arise as an promis-
ing route to carry and deliver biomimetic molecules and 
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drugs in an attempt to overcome such medical complica-
tions (Figure 3).118
Acellular Self-Assembled Peptide 
Hydrogels as Biologics for Heart 
Attack Treatment
The formation of fibrotic tissue during AMI is one major 
concern in medicine. Therefore, efforts are being carried out 
to prevent and to reduce fibrosis during tissue repair in 
patients undergoing AMI.22 In this context, composite hydro-
gels have been designed from natural-derived materials, such 
as chitosan, collagen, and hyaluronic acid, which have suc-
ceeded to encapsulate and deliver various growth factors, 
such as angiopoietin-1, insulin-like growth factor-1 (IGF- 
1), VEGF, and stromal cell-derived factor 1α (SDF- 
1α).92,119–121 However, over naturally derived scaffolds, 
SAPHs arise as advantageous scaffoldings in terms of repro-
ducibility and stability, since they avoid batch-to-batch varia-
bility, which is significant for biomedical applications.122–124
Recently, Han et al designed the PGN peptide hydrogel 
from two short peptide sequences GHRPS, a secretagogue 
known to offer cardioprotective activity, and GTAGLIGQ a 
peptide that belongs to matrix metalloprotease-2 (MMP-2). 
The latter has been incorporated into the system to assist in 
the disassociation of PGN. Additionally, naphthalene acetyl 
tail linked to the N-terminus of a phenylalanine dipeptide or 
NapFF was incorporated to promote gelation. The PGN 
hydrogel supported the viability of murine myoblasts under 
oxidative stress conditions, which might be due to GHRPS. 
Furthermore, exosomes derived from human mesenchymal 
cells (derived from the umbilical cord) encapsulated in the 
PGN gel, favored the expression of transforming growth 
factor-beta (TGF-β), whilst the infiltration of inflammatory 
cells decreased once such formulation was transferred into an 
infracted model in vivo. Moreover, the formation of fibrotic 
tissue was significantly reduced, whereas angiogenesis 
improved for 28 days after intracardiac gel treatment.125
Similarly, RADA16-II was functionalized with the pep-
tide sequence CDDYYYGFGCNKFCRPR to mimic the 
bioactivity of Notch 1 ligand (regulator of cell proliferation, 
maturation, and apoptosis). RADA16-CDDYYYGFGCN 
KFCRPR decreased fibrosis, stimulated angiogenesis, and 
favored the recruitment of stem cells in an infracted model 
in vivo.22
Figure 3 Schematic representation of self-assembling peptide hydrogels for cardiovascular tissue regeneration. Growth factors, drugs or stem cells are incorporated in 
peptide hydrogels to promote cardiac tissue healing.
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Therefore, the studies presented emphasize the key role 
that biofunctionalized SAPHs have to improve cardiac 
functions and cardiac tissue regeneration in a simplistic 
and cost-effective manner with no need of incorporating 
whole proteins or complicated chemistry strategies.
Previously, Kim et al encapsulated both the platelet- 
derived growth factor (PDGF) and FGF2 in RADA16-II 
for their progressive and sustained delivery once trans-
ferred into an infarcted heart model. The administration 
of RADA16-II gel significantly reduced apoptosis, as well 
as cardiac wall thickness, which improved cardiac func-
tions during 4 weeks of treatment91 as represented in 
Figure 3.
Moreover, two hydrophobic cardiovascular drugs, 
Quinine and Pindolol (non-selective adrenergic receptor 
blockers) were successfully incorporated within 
RADA16-II peptide hydrogel to promote their retention 
and sustained releasing. The incorporation of such drugs in 
RADA16-II did not affect its β-sheet conformation nor its 
self-assembly. After the encapsulation of the hydrophobic 
drugs in gels, their cumulative and sustained release could 
be successfully achieved in one week. According to the 
authors, such drug retention and release were significantly 
promoted by electrostatic interactions occurring between 
the aromatic rings of medications and the nanofibers form-
ing RADA16-II. This outcome was also dependent on the 
isoelectric point of medications (close to pH 7), Log P, and 
the type of saline buffers used to dilute the drugs. Hence, 
further investigations must to be carried out for a deeper 
understanding of the physicochemical mechanisms (for 
example, drug diffusion) under physiological pH to allow 
the delivery of cardiovascular drugs from RADA16-II 
gels.90
Self-Assembled Peptide Hydrogels 
as Cell-Load Biologics for Heart 
Attack Treatment
Over the years, the transfer of stem and mature cells 
became as a general approach to the treatment of CVDs, 
such as AMI, in an attempt to restore cardiac functions in 
vivo. Nonetheless, poor cell retention and impaired stem 
cell differentiation are concerns that still limit such a 
strategy.126–129
In this context, RADA16-II as a three-dimensional 
depot of cells supported the viability of murine MSCs 
once transferred into beating hearts of rats subjected to 
coronary artery ligation. Thereafter, gel treatment 
improved cardiac functions and decreased ventricular dila-
tation in 28 days. In addition, a high rate of genes related 
to tissue repair, and an anti-inflammatory response could 
be recorded in the myocardium, as well as the formation of 
microvasculature and a reduced deposition of interstitial 
collagen could be observed after hydrogel treatment in 
vivo. It is believed that such outcomes could be derived 
from the paracrine activity of MSCs once delivered from 
RADA16-II. According to the authors, RADA16-II can be 
easily prepared and applied by practitioners, which is a 
major advantage for biomaterials intended for clinical 
applications.24
In order to direct stem cell differentiation, the nanofi-
brillar-based peptide hydrogel DFEFKDFEFKYRGD, was 
used to encapsulate murine MSCs genetically modified to 
increase the production of the hepatocyte growth factor 
(HGF), which has shown to play a key role as an antifi-
brotic, proangiogenic and cardioprotective molecule. The 
transfer of the peptide hydrogel harboring the engineered 
MSCs into infarcted animals promoted a significant 
improvement in heart functions as scarring in myocardial 
tissue decreased as represented in Figure 3. Furthermore, it 
was suggested that DFEFKDFEFKYRGD was key to facil-
itate cellular adhesion, viability and the commitment of 
MSCs into a cardiomyocyte profile.130
The double functionalization of RADA-16-II with 
RGD and KLT (the latter known to provide angiogenic 
activity) also showed a remarkable retention of murine 
bone marrow mesenchymal stem cells once transferred 
into murine cardiac tissue. Furthermore, reduced infarcted 
areas and the proliferation of cardiomyocytes were evi-
denced after 28 days of hydrogel treatment,131 which is in 
good agreement with the research carried out by Li and 
Guo, who showed that RADA16-RGD significantly pro-
moted the retention of marrow derived cardiac stem cells 
(MCSCs), when cultured on gels under anoxic and low 
glucose conditions in vitro. Moreover, RADA16-RGD 
hydrogels significantly repaired myocardium and 
improved cardiac functions as myocyte contractions 
increased and the reduction of collagen deposition was 
observed in a murine AMI model.132
The capability of RADA16-II to maintain the plasticity 
of human induced pluripotent stem cells (hiPSCs) under 
3D conditions has been explored to develop bioactive 
patches capable of promoting myocardial reparation. 
Molecular biology tests showed that hiPSCs in 
RADA16-II showed good viability and maintained their 
plasticity, since POU5F1 and FOXA2 were upregulated 
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and downregulated, respectively under ascorbic acid (a 
cell differentiation inducer) stimulation for 20 days of 
3D culture. Additionally, the expression of the gene 
TBX5 (another cardiac progenitor), was unchanged under 
the same cell culture conditions. On the other hand, 
hiPSCs expressed the cardiac lineage genes GATA4 and 
TBX5, and downregulated the expression of POU5F1 (a 
pluripotential marker) under ascorbic acid stimulation by 
using standard cell cultures. These data strongly suggest 
that RADA16-II is a useful scaffold to encapsulate and 
deliver pluripotent cells in a well-controlled manner with-
out inducing premature cell differentiation, which repre-
sents a significant advantage to direct cellular 
differentiation to ultimately help with the formation or 
repair of cardiovascular tissues. However, further studies 
for a better understanding of the plasticity of hiPSCs in 
RADA16-II hydrogels for the treatment of cardiovascular 
tissue would be needed.133
Similarly, in 2014 Soler et al developed a cardiac 
implant from RADA16-II, in which they encapsulated 
progenitor cells derived from subcutaneous adipose tissue 
(SubATDPCs) of patients undergoing cardiac surgery. This 
approach focuses on directing cardiac cell differentiation 
after hydrogel implantation into an AMI model to promote 
the regeneration of affected cardiac tissue as exemplified 
in Figure 3. Interestingly, the viability of SubATDPCs 
significantly improved, and blood vessel formation was 
observed, which134 is in good agreement to previous stu-
dies showing the suitability of RADA16-II to support the 
3D culture of cardiac cells to prevent irregular contractions 
of cardiomyocytes.135 However, regarding previous 
research, it is necessary to explore in a deeper way the 
cardiac tissue functions, where immunological reactions 
can be discarded as for premature disassociation of gels 
to facilitate the clinical transfer of RADA16-II to restore 
cardiac malfunctions.
Self-Assembled Peptides as Cell- 
Load Biologics for Treating Other 
CVD Disorders
One major goal for biomedicine is finding novel alterna-
tives to replace damaged vascular tissue. Today, one gen-
eral approach to overcome such medical complication 
includes vascular grafting. However, following grafting 
surgery, restenosis, partial endothelialization and thrombo-
sis are some vascular complications related to grafting that 
still need improvements. In this matter, recent studies 
explore the capability of peptide hydrogels to form vascu-
lar-like nanostructures matrices to restore the architecture 
and function of vessels.93 For instance, the double functio-
nalization of RADA16-II with QLK and LRK peptides has 
explored to induce the formation of vascular tissue. The 
peptide QLK is known to bind transglutaminase (via cova-
lent interactions), whose function is to provide protection 
to growth factors from proteolytic degradation, while LRK 
has the capability to join angiogenic inducers, such as 
HGF, and VEGF. Therefore, through blending RADA16- 
QLK and RADA-LRK peptides, a double functionalized 
RADA-QLK-LKR was formed and transferred onto 
chicken chorioallantoic membranes to induce the forma-
tion of blood vessels-like tissue in situ. The retention of 
the functionalized RADA-II peptide gel was significantly 
facilitated by strong electrostatic interactions between 
LRK and heparan sulfate. Through a minimalist approach, 
the peptide hydrogel supplemented with VEGF and HGF 
also supported the culture of human umbilical vein 
endothelial cells (HUVECs) when cultured on gels, as 
well as the formation of capillary-like tubular structures 
at 8 hours of culture in vitro.93
Similarly, McClendon et al used the amphiphilic pep-
tide C16-V3A3E3 (NH2) to form a hydrogel mimicking the 
tubular shape of coronary arteries. To achieve this, the 
amphiphile peptide solution was injected into a shear 
flow chamber, which, subsequently, was placed into saline 
solution to induce gelation. After this, human smooth 
muscle cells were encapsulated in the peptide gel and 
were subjected to contractional and rotational motion in 
order to emulate blood flow and endothelial contraction. 
The viability of cells was steady, and interestingly, cells 
acquired an elongated morphology after 12 days of cul-
ture. In addition, cells were capable of migrating to the 
surface of hydrogels and aligned throughout the tubular 
shaped gel, where higher rates of cellular growth were 
recorded in comparison to cells not subjected to contrac-
tional and rotational stimuli. The outcome reported from 
this study, makes amphiphile peptide hydrogels appealing 
scaffolds to form tubular structures capable of repairing 
damaged arteries in patients with heart disease.136
Through a different approach to target vascular disor-
ders, the role that NO has to foster the proliferation of 
smooth cells has been evaluated, since NO is known to be 
a natural mediator of vascular homeostasis and an inducer 
of endothelial cells proliferation. Therefore, the amphi-
phile peptide hydrogel GTAGLIGQ was functionalized 
with both, YIGSR and KKKKK, which are laminin- 
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derived adhesion and nitrogen oxide (NO) donating moi-
eties, respectively. The peptide gel also incorporated a 
MMP2 mediated cleavage site to favors its progressive 
enzymatic degradation and the subsequent release of 
YIGSR and KKKKK. Thereafter, the hydrogel was used 
as a coating for silicone-based cell cultures chambers, 
which were supplied with NO. The incorporation of NO 
into the cell culture chambers and its subsequent release 
from cell culture significantly enhanced the adhesion and 
proliferation of endothelial cells, contrary to the observed 
with smooth muscle cells, whose proliferation was limited 
after 48 h on 2D cultures.137 Consequently, this approach 
might be useful to improve the conditions of cardiovascu-
lar implants and reduce risks associated to cardiovascular 
therapeutics in the near future.
Atherosclerosis is another cardiovascular condition that 
requires more effective therapies. Therefore, the propen-
sity of the short bioactive peptide hemopressin 
(PVNFKFLSH) to form β-sheet-based nanofibrillar 
matrices to prevent atherosclerosis was investigated. 
Hemopressin is known to inhibit food intake in vivo 
through an antagonist effect on the cannabinoid receptor 
CB1. According to some authors, synthetic hemopressin 
(PVNFKFLSH) is able to self-assembly under physiologi-
cal pH environments, however, the formation of ordered 
and unordered nanostructures from such peptide has also 
been reported. Although, this strategy represents a plausi-
ble route for discovering novel pharmaceutics to address 
atherosclerosis, further research would be needed to fully 
understand the hierarchical assembly of PVNFKFLSH to 
discard the risk of any peptide fibrillization that may carry 
non-desirable biological effects.138
In this context, another research studied the capability 
of the self-assembling cyclic peptide c(wLwReQeR) to 
control the morphology and function of the high-density 
lipoprotein (HDL). Importantly, the architecture of the 
HDL molecules is strongly linked to their capability to 
regulate cholesterol levels in blood. The cyclic peptide c 
(wLwReQeR) was designed to form structured nanotubes 
capable of arresting lipids from HDL particles, and subse-
quently, of increasing the formation of lipid-poor HDL or 
pre-beta-HDL in vitro and in vivo. The mechanisms 
involved in this approach are not yet fully understood, 
however, according to the authors the cyclic peptides are 
capable of displacing the apoA-I protein forming HDL 
particles, which ultimately favors the releasing of the 
lipid-free apoA-I. Therefore, the latter molecule is capable 
of accepting lipids and cholesterol facilitating the 
subsequent transport and degradation of apoA-1. This 
useful approach might avoid the accumulation of apoA-1 
in vessels, and thus, controlling the progression of athero-
sclerotic plaques.139
Pathway Towards Development of 
Medicinal Products Based on Self- 
Assembling Peptides for Clinical 
Treatment of MS Conditions
In the last two decades, there has been a surge of endea-
vours to develop therapeutic systems based on self-assem-
bling peptides for various medical conditions, with most 
research carried out focusing on regenerative medicine and 
drug delivery approaches. The majority of these studies 
were confined to proof-of-concept with insufficient pre- 
clinical research, which refrain the progression towards 
clinical trials. Leading medical regulatory authorities 
worldwide, such as the US Food and Drug Admnistration 
(FDA), Medicines and Healthcare products Regulatory 
Agency (MHRA) in the UK, European Medicines 
Agency (EMA), and Ministry of Health, Labour and 
Welfare (MHW) of Japan, have set rigorous regulations 
for clinical trial authorization of any medicinal product or 
device; with the patient’s safety, and product quality, and 
efficacy at the centre of the development process. 
Common quality, safety, and efficacy guidelines have 
been agreed between the aforementioned leading authori-
ties and pharmaceutical industry through the International 
Council for Harmonisation (ICH) of technical and scien-
tific requirements for products for human use.140 These 
guidelines should be followed throughout all development 
stages of self-assembling peptide products for clinical use 
including those intended for treatment of MS conditions. 
In this section, we will shed the light on few examples of 
studies that reported preliminary pre-clinical results that 
have good chances of clinical translation with more exten-
sive studies needed to meet the pre-clinical requirements 
of regulators for clinical trials authorization.
As discussed earlier in our recent review, good steps 
have been taken towards developing advanced biomater-
ials for the cellular and acellular treatment of diabetes 
mellitus (DM) and associated complications, which led to 
few FDA approved products.86 However, systems based 
on self-assembling peptides have not gone that far. A pre- 
clinical study showed promising results for the cellular 
treatment of DM using self-assembling heparin-binding 
peptide amphiphiles nanofibers for the delivery of vascular 
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endothelial growth factor (VEGF) and FGF-2, which suc-
cessfully induced vascularisation and improved engraft-
ment of isologous islets of Langerhans when transplanted 
in diabetic mouse with maintaining normoglycemia in 
high proportion of the tested animals 
(Table 4).98PuraMatrixTM peptide hydrogels on the other 
hand were used for the acellular drug treatment of DM, 
where hydrogels were used as vehicles for the sustained 
release of murine insulin post-subcutaneous injection in 
rats. Sustained release of murine insulin was achieved 
from this simple formulation, which maintained low 
blood glucose level for 24 hours in rats.97 A smart glucose 
responsive hydrogel system has also been reported and 
showed a good potential for the on-demand insulin release 
for clinical translation. The system is based on the self- 
assembling β-hairpin forming IA-2 peptide hydrogel 
loaded with glucose oxidase (GO) and bovine insulin 
(Table 4).141 In hyperglycaemia conditions, GO acts as a 
catalyst that converts glucose to gluconic acid, lowering 
the hydrogel pH and cationic residues become charged 
leading to repulsion and unfolding of peptide chains and 
consequently disassembly and insulin release. The system 
proved to work very well in vivo providing physiological 
control of insulin release, where diabetic mice treated with 
this formulation showed higher blood insulin concentra-
tions and reduction in glucose levels compared to groups 
treated with insulin loaded hydrogels without GO.141
Chronic wounds and ulcers are of the main complica-
tions associated with DM, which can eventually lead to 
limb surgical amputation in severe conditions.142 Heparin- 
like amphiphilic peptide hydrogels improved wound heal-
ing in diabetic mice, as it forms a biomimetic scaffold 
functionalized with the negatively charged heparin sul-
phate proteoglycans, hence, capable of binding the angio-
genic factor VEGF and the fibroblast growth factor FGF-2 
(Table 4).143 This system provides both structural and 
functional attributes that enhanced vascularization, expres-
sion of α-smooth muscle actin (α-SMA), collagen deposi-
tion and re-epithelisation, as well as the induced reduction 
in the levels of inflammatory cytokines (IL-6 and TNF-α) 
levels. Good chances can be seen here for formulation 
prototype development of a pharmaceutical product for 
the treatment of diabetic chronic wounds and ulcers.143 
Another complication associated with DM is the erectile 
dysfunction in male patients, which was shown to be 
closely related to the high collagen levels in cavernous 
tissue. Interestingly, a recent study showed that significant 
reduction of the cavernosa collagen levels of rat models 
was observed over on 4 days after localized injection with 
Sonic Hedgehog loaded amphiphilic peptide hydrogels 
(Table 4). This approach introduces a new therapeutic 
strategy for erectile dysfunction in male diabetic 
patients.144
For the treatment of myocardial infarction, the devel-
opment of cardiac patches based on self-assembling pep-
tide for the cellular therapy of myocardial infarction has 
been patented. The patch is a prototype of a medical 
device composed of stitchable biodegradable polyur-
ethane-based film support covered with a polycaprolactone 
(PCL) based biopolymer composite, which is impregnated 
with an ionic-complementary β-sheet forming peptide 
hydrogel as a nanofibrous functionalized scaffold that 
mimics extracellular matrix microenvironment. Patches 
implanted on the left ventricle of rats after heart cryoinjury 
showed to be stable for 4–10 days after implantation and 
provided structural support to damaged tissue without 
signs of inflammation. The patent suggested that this 
device is adequate for autologous stem cells implantation 
not only for cardiac tissue engineering, but also for any 
soft tissues.145
Another example of pre-clinical studies for myocardial 
infarction treatment involved the use of the insulin-like 
growth factor 1 (IGF-1) functionalized peptide nanofibers. 
In this system, the biotinylated cardiomyocyte IGF-1 was 
conjugated with streptavidin, which in turn was complexed 
with the biotinylated self-assembling ionic-complementary 
RADA16-II peptide forming IGF-1 functionalized β-sheet 
nanofibers. Preliminary in vivo studies showed that the 
biotin “sandwich” conjugate has supported cardiac tissue 
repair, where it provided sustained delivery of IGF-1 for 
28 days, post-injection into rat myocardium. When com-
bined with cardiomyocytes transplantation, the growth 
factor-peptide nanofibers conjugate not only acted as a 
sustained delivery vehicle for IGF-1, but also as a 3D 
scaffold system for transplanted cells, thus significantly 
improving cardiac tissue structure as evident by increased 
cross-sectional area and function by improving systolic 
activity (Table 4). Local myocardial insulin-like growth 
factor 1 (IGF-1) delivery with biotinylated peptide nano-
fibers improves cell therapy for myocardial infarction.120
Another study demonstrated the multifunctional role of 
RADA16-II peptide nanofibers as biomimetic 3D cell 
scaffolds for recruiting endothelial and vascular smooth 
muscle cells and as a delivery vehicle for the angiogenic 
fibroblast growth factor-2 (FGF-2) and the arteriogenic 
platelet-derived growth factor-BB (PDGF-BB); a new 
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approach for myocardial infarction treatment.91 In this 
study, infarcted heart mice treated with the dual growth 
factor loaded RADA16-II hydrogels showed significant 
cardiac protection through enhanced vascularisation and 
inhibition of fibrosis compared to all control groups. 
Peptide-based scaffoldings and their capability to be func-
tionalized or combined with a plethora of biological com-
ponents are exemplified in Table 4.
The above-chosen examples have very good chances 
for clinical translation; however, the main challenge for 
Table 4 Depiction of Bottom-Up Design Approach for De Novo Peptides Capable of Self/Co-Assembly into Different Classes of 
Bioinspired Nanofibrous Structures Forming Hydrogels.
Therapeutic 
Molecule
Self-Assembling Peptide System MS 
Condition










Sustained myocardial growth factor 
delivery improved cardiac cross-sectional 









Combination therapy. Protect cardiac tissue 
by inhibiting fibrosis and enhancing 
vascularity. Peptide nanofibers act as 3D 
scaffolds for recruiting endothelial and 
vascular smooth muscle cells, and as a 
delivery system for angiogenic growth factor 
FGF-2 and arteriogenic growth factor 
PDGF-BB.
Pre-clinical 91
N/A Cardiac patch including a PCL-based 
biopolymer composite layer 
impregnated with β-sheet ionic- 





Layer of peptide-functionalized biopolymer 
composite that acts as biomimetic 






Heparin-binding peptide amphiphiles. Diabetes 
mellitus
Delivery of growth factors that enhanced 











Sustained delivery of murine insulin post 
subcutaneous injection.
Pre-clinical 97
Bovine insulin. β-hairpin peptide. 
IKIKIKIK-IDPPT-KIOIKIKI-NH2 
(IA2) with glucose oxidase.
Diabetes 
mellitus.
Glucose responsive hydrogel system for 
the controlled on-demand release of 
insulin.
Pre-clinical 141
N/A Heparin-like amphiphilic peptide. Diabetic foot 
ulcer.
Enhanced vascularization, expression of α- 
smooth muscle actin (α-SMA), collagen 
deposition and re-epithelization, as well as 
induced reduction in the inflammatory 











Localized delivery of Sonic Hedgehog, 
which decreases collagen production in 
erectile fibres and enhance erectile 
function.
Pre-clinical 144
Abbreviations: MS, metabolic syndrome; IGF-1, insulin-like growth factor-1; FGF-2, fibroblast growth factor-2; PDGF-BB, platelet-derived growth factor-BB; VEGF, vascular 
endothelial growth factor.
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the clinical authorization here is the complicated nature of 
the prospective product, which is, in most cases, composed 
of three main components: self-assembling peptide nanos-
tructures, growth factors or drug molecules, and cells 
(Figure 4).Therefore, more extensive pre-clinical testing 
following regulatory guidelines should be performed. 
This will involve, for instance, stability studies of the 
self-assembled peptide systems and the drug payload, 
level of impurities and evidence of good manufacturing 
practice in the development of the formulation or scaffold 
components.146 In addition, a full pre-clinical safety eva-
luation of the new systems should be performed, such as 
carcinogenicity, genotoxicity, reproductive toxicity and 
immunotoxicology studies.147 Moreover, a full evaluation 
of the specific quality and safety measures for 
biotechnological, cell therapy, and tissue engineering pro-
ducts is essential in case of the use of growth factors and/ 
or cells in the product. For instance, viral safety must be 
assured, cells viability in formulation and after adminis-
tration, maintenance of genotype or phenotype for the 
intended treatment, etcetera146,148 as indicated in the ICH 
quality guidelines of technological product (Q5A-Q5E)146 
and the EMA guidelines on human cell-based medicinal 
products.148 We believe that meeting the expectations of 
the regulators expectations equates with great potential of 
success for the bench-to-bed side development of self- 
assembling peptide products for clinical treatment of MS 
conditions. This success relies on the efficient interaction 
between research groups in universities, the pharmaceuti-
cal and biotechnology industry, and the regulators.
Figure 4 General outline of the peptide-based therapy (hydrogels, solutions, other matrices) for the treatment of metabolic syndrome and related comorbidities. Bioactive 
molecules, drugs or cells are usually incorporated in peptide-based nanostructures to provide them with specific therapeutic functionality.
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Conclusion
Metabolic syndrome is an unmet medical condition, which 
requires novel therapeutics to prevent and address its related 
comorbidities. In this context, self-assembled peptides repre-
sent a promising approach to overcome the limitations of 
current MS treatment. The recent studies discussed here shed 
light on the potential of self-assembling peptide nanostructures 
as a useful route for the discovery of novel drugs or to 
improvement of the current pharmaceuticals to face MS and 
derived diseases. Nevertheless, despite the physicochemical 
advantages that peptide-based technology offers in the biome-
dical field for regenerative medicine, tissue engineering and 
the pharmaceutical industry, only a limited peptide-based 
technology has reached clinical trials. This might be due to 
peptide-based nanomaterials as cutting-edge biotechnology 
still face some challenges to overcome, which include avoid-
ing any potential immunogenicity reactions derived from 
novel peptide formulations designed, limited standardization 
protocols realted to the rate of biomolecules incorporated in 
peptide-base nanostructures to orchestrate biological func-
tions, as well as short-term stability of peptide formulations 
when challenged under physiological conditions. Therefore, it 
is of paramount importance to carry out immunological stu-
dies in a deeper manner to identify any possible non-desirable 
immunogenicity derived from novel peptide-based formula-
tions developed. Likewise, it may be advisable to extend 
evaluations of the biological responses after the rational incor-
poration of extracellular matrix peptide moieties, whole pro-
teins, or drugs at different rates within peptide formulations. 
The aforementioned recommendations should be taken into 
account either at laboratory stages (ideally using human cells 
as biological platform to test the effect of peptide nanostruc-
tures developed) or during clinical stages following the recom-
mendations of medical regulatory authorities. Moreover, we 
suggest the use of a double network approach when designing 
novel peptide-based nanomaterials, which could significantly 
improve their polymeric network density/strength and 
mechanical stability, while retaining their biological activity. 
Therefore, the transition from technological laboratory devel-
opments to the launch of peptide-based pharmaceutical pro-
ducts to meet MS, still requires further research efforts, where 
both research institutes and industry represent the fundamental 
basis to achieve such a goal.
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